華東醫藥(000963.SZ):子公司與澳宗生物簽署產品獨家許可協議
格隆匯7月14日丨華東醫藥(000963.SZ)公佈,2024年7月12日,公司全資子公司杭州中美華東製藥有限公司(稱“中美華東”)與蘇州澳宗生物科技有限公司(稱“澳宗生物”)簽訂了產品獨家許可協議(稱“《合作協議》”)。中美華東獲得澳宗生物的TTYP01片(依達拉奉片)(稱“許可產品”)所有適應症在中國大陸、香港、澳門和台灣地區(稱“許可區域”)的獨家許可,包括開發、註冊、生產及商業化權益。中美華東將向澳宗生物支付10,000萬人民幣首付款,最高不超過118,500萬人民幣的開發、註冊及銷售里程碑付款,以及分級最高達兩位數的淨銷售額提成費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.